Navigation Links
Identified a subgroup of schizophrenia patients with motor disorders

Researchers led by Marta Barrachina, Institute of Neuropathology of the Bellvitge Biomedical Research Institute (IDIBELL) have identified a new subgroup of patients suffering from schizophrenia characterized by motor disorders.

The results of the study, which was conducted in collaboration with the research team Mairena Martin at the University of Castilla La Mancha at Ciudad Real and clinical researchers of the Health Park Sant Joan de Deu at Sant Boi de Llobregat, have been published in the online edition of the Journal of Psychiatric Research and was funded by the TV3 Marathon in the 2008 edition.

Schizophrenia is a serious mental illness. From a clinical point of view is considered grouping several diseases that are not well defined or characterized by biomarkers.

Barrachina team studies the A2A adenosine receptor, which is highly expressed in the basal ganglia at the central nervous system and is involved in the control of movement. Furthermore this protein inhibits the activity of dopamine D2 receptor, hyperactivated in schizophrenia patients and typical antipsychotics target.

"We studied the post- mortem brains of patients," explains Barrachina "and we found that 50% had very low levels of adenosine A2A receptor. Interestingly, when comparing these data with clinical information provided by the clinical investigators of the study, we note that these patients had motor disorders." "In addition, we identified an epigenetic mechanism associated with the decreased receptor expression."

According to the researcher, this finding allows to "identify a new subset of schizophrenia patients with motor disorders."

Proposal for combined therapy

This study opens the door to a clinical trial, based on radioimage, which would detect the levels of this protein and identify these patients and also to confirm the results obtained in the postmortem brains of patients. Barrachina team proposes to apply a specific combination therapy of antipsychotics and agonists of A2A adenosine. "Thus, the activity of adenosine A2A receptor will be favoured, reducing the dose of antipsychotics."


Contact: Arantxa Mena
IDIBELL-Bellvitge Biomedical Research Institute

Related biology news :

1. First dinosaurs identified from Saudi Arabia
2. New anti-HIV drug target identified by University of Minnesota researchers
3. Scientists identified T372R mutation as potential target for diagnosis and treatment of insulinoma
4. New target identified for preventing bone destruction in diseases such as arthritis and cancer
5. Treatment target identified for a public health risk parasite
6. Genetic signature identified for RSV, the leading cause of infant hospitalizations worldwide
7. Newly identified proteins make promising targets for blocking graft-vs.-host disease
8. New target to fight HIV infection identified
9. Baculovirus-recognizing human cell receptor identified for the first time
10. New dwarfism mutation identified in dogs
11. Inflammatory on and off switch identified for allergic asthma and COPD
Post Your Comments:
(Date:12/1/2015)... 2015 Synaptics Incorporated (NASDAQ: SYNA ), ... a new agreement with Nok Nok Labs ... development environments that combine FIDO Certified ™ Synaptics ... complexity of FIDO certification for Synaptics, customers. Using Nok ... to verify FIDO enabled devices in real-world authentication scenarios. ...
(Date:11/30/2015)... 2015  BIOCLAIM announced today that is has ... Innovation Awards:  Healthcare Edition, an awards program from ... FierceHealthcare , and FierceMobileHealthcare ... the category of "Privacy and Cybersecurity." ... --> Photo - ...
(Date:11/26/2015)... 2015 Research and Markets ( ) ... Sensors - Technology and Patent Infringement Risk Analysis" ... --> Fingerprint sensors using capacitive technology ... fingerprint sensor vendor Idex forecasts an increase of 360% ... devices and of the fingerprint sensor market between 2014 ...
Breaking Biology News(10 mins):
(Date:12/1/2015)... 2015 Oxford Finance LLC ("Oxford"), a specialty ... and healthcare services companies, today announced the closing of ... Inc. ("the Company"). Proceeds from the loan are being ... Company,s Rejuvaphyl™ and daily skincare products. ... brand of high potency skincare products that contain the ...
(Date:12/1/2015)... 1, 2015  The Minnesota High Tech Association (MHTA) ... Tekne Award in the Small and Growing Healthcare award ... Minneapolis Convention Center, the Tekne Awards ... role in developing new technologies that positively impact the ... Clostridium difficile infection ( C. diff. ...
(Date:12/1/2015)... Dec. 01, 2015 ... of the "2016 Europe Cell Surface ... Technologies, Competitive Strategies, Opportunities for Suppliers--France, Germany, ... offering. --> ) has ... Europe Cell Surface Markers: Country Volume and ...
(Date:12/1/2015)... Dec. 1, 2015  CardioCell LLC, a Stemedica ... cells for cardiovascular indications, intends to proceed with ... on recommendations from a Heart Failure Advisory Board ... Scientific Advisory Board members . In a recent ... IIa safety and efficacy data from CardioCell,s on-going ...
Breaking Biology Technology: